Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Accredo Health Group Inc (NPI 1346208949)

Field	Value
Entity Type	Organization
Organization	Accredo Health Group Inc
Address	1620 Century Center Pkwy Ste 109
City	Memphis
State	TN
ZIP	38134
Taxonomy	Pharmacy
NPI Enumerated	May 3, 2006

Payer Source	Total Paid
Medicaid	$165.6M
Medicare	$0

Key Findings

This provider has no Medicare billing on file and is effectively single‑payer from a claims perspective, with all reported federal revenue coming from Medicaid. Lifetime Medicaid revenue on file is $165.6M, so analyses of scale, concentration, and market role should be viewed through a Medicaid-only lens.

Revenue is highly concentrated: the precomputed top‑three Medicaid codes account for 70.4% of this provider's total Medicaid revenue. The single largest driver is J2326 ($80.9M, 48.9% of total), followed by J2357 ($20.7M, 12.5%) and Q9992 ($15M, 9.1%), indicating that a small set of products dominates the revenue base.

The code mix identifies ACCREDO HEALTH GROUP INC as a specialty pharmacy/infusion-oriented operation that dispenses high-cost biologics and long‑acting injectables. High-revenue codes include nusinersen (J2326), omalizumab (J2357), and extended‑release buprenorphine (Q9992/Q9991), while other billed items (e.g., J0585 onabotulinumtoxina, J3285 treprostinil, J7686 inhaled treprostinil, and S9347 home infusion) point to services spanning specialty pharmacy distribution, infusion support, and complex chronic-disease therapies. This mix is consistent with a business model focused on managing and dispensing specialty injectables rather than standard retail pharmacy volumes.

ACCREDO shows a dominant statewide footprint on multiple codes: it ranks #1 in-state for many of its top lines. Specific examples include J2326 (rank #1 of 1 providers in-state, no peer volume comparison available), J2357 (rank #1 of 4, 100th percentile) and Q9992 (rank #1 of 3, 100th percentile). Notably, J0585 (onabotulinumtoxina) is listed as an "extreme outlier" and the provider ranks #1 of 18 for that code, indicating far higher state volume than peers for that specific product.

Beyond the top three, the provider bills a range of specialty therapies and support services that diversify clinical exposure: J3285 treprostinil ($3.9M), 90378 immunoglobulin ($3.2M), J7686 inhaled treprostinil ($2.8M), and J1726 hydroxyprogesterone caproate ($2.6M). The presence of S9347 (home infusion per diem) and A4221 (infusion supplies) supports an operational capability in home or long‑term infusion administration in addition to pharmacy dispensing.

Claim-level patterns show a mix of very-high-cost, low-volume items and high-volume, lower-per-claim items. J2326 posts 953 claims with an avg paid/claim of $84903, while Q9992 and Q9991 show large claim counts (9.5K and 7.7K claims respectively) with avg paid/claim around $1582–$1554, and J2357 appears as high-volume for a specialty biologic (8.4K claims, $2456 avg paid/claim). This combination implies revenue driven both by a small number of extremely costly doses and by scale in dispensing long‑acting injectable therapies.

The provider has an established tenure in the NPI registry, enumerated 2006-05-03 (~20 years ago), which—together with a $165.6M Medicaid revenue footprint and top-state rankings on several products—suggests a mature specialty pharmacy or infusion business with entrenched contracts or distribution capabilities in Tennessee.

Concentration on a handful of very expensive therapeutics creates exposure to utilization or reimbursement changes for those drugs but also reflects strategic positioning: the firm is a statewide leader on multiple specialty codes and participates across addiction treatment (Sublocade Q9992/Q9991), respiratory and pulmonary hypertension therapies (treprostinil codes), rare-disease/high-cost biologics (J2326, J0584), and immunoglobulin/infusion services. That breadth across specialty niches can be both an opportunity for continued Medicaid growth and a risk if policy or clinical demand shifts for any of the dominant products.

Medicaid: Complete Services Breakdown

Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.

28 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2326	Injection, nusinersen, 0.1 mg	950	$84,900	$80.9M
J2357	Injection, omalizumab, 5 mg	8,420	$2,460	$20.7M
Q9992	Injection, buprenorphine extended-release (sublocade), greater than 100 mg	9,510	$1,580	$15M
Q9991	Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg	7,720	$1,550	$12M
J0585	Injection, onabotulinumtoxina, 1 unit	7,840	$1,040	$8.1M
J3285	Injection, treprostinil, 1 mg	590	$6,600	$3.9M
J0517	Injection, benralizumab, 1 mg	950	$3,880	$3.7M
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	1,000	$3,680	$3.7M
90378	Immunoglobulin is a very complex protein that is produced by certain cells in the body to protect it from various types of infections and produce passive immunity. RSV–IgIM (respiratory syncytial…	1,520	$2,120	$3.2M
J0584	Injection, burosumab-twza 1 mg	180	$17,200	$3.1M

Showing 1–10 of 28

Medicaid: Competitive Analysis & Benchmarks

How this provider's Medicaid billing volume and revenue compare to other Tennessee providers billing the same CPT/HCPCS codes.

Claims Volume vs. Tennessee Distribution

Accredo Health Group Inc — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. Tennessee median

28 rows

CPT/HCPCS Code	Description	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2326	Injection, nusinersen, 0.1 mg	1	10	950	$84,900	$80.9M
Q9992	Injection, buprenorphine extended-release (sublocade), greater than 100 mg	1	10	3,120	$1,620	$6.8M
J2357	Injection, omalizumab, 5 mg	1	10	420	$2,390	$5.5M
Q9991	Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg	1	10	2,020	$1,600	$5.2M
J1726	Injection, hydroxyprogesterone caproate, (makena), 10 mg	4	10	1,310	$830	$4.8M
J3285	Injection, treprostinil, 1 mg	1	10	590	$6,600	$3.9M
J0517	Injection, benralizumab, 1 mg	1	10	950	$3,880	$3.7M
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	1	10	1,000	$3,680	$3.7M
J0584	Injection, burosumab-twza 1 mg	1	10	180	$17,200	$3.1M
J7686	Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg	1	10	1,590	$1,770	$2.8M

Showing 1–10 of 28

Related Providers

Other providers that share a Tax Identification Number (TIN) with Accredo Health Group Inc, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Laboratory Corporation Of America Holdings	NC	Clinical Medical Laboratory	$214.6M	$1.4B
Laboratory Corporation Of America Holdings	NJ	Clinical Medical Laboratory	$143.3M	$717.5M
Natera, Inc.	CA	Clinical Medical Laboratory	$133.1M	$641.5M
Unilab Corporation	CA	Clinical Medical Laboratory	$94M	$668.5M
Bioreference Health, LLC	NJ	Clinical Medical Laboratory	$66.8M	$620.1M
Laboratory Corporation Of America Holdings	OH	Clinical Medical Laboratory	$56.9M	$617M
Millennium Health, LLC	CA	Clinical Medical Laboratory	$20.4M	$579.3M
Exact Sciences Laboratories, LLC	WI	Clinical Medical Laboratory	$299.3M	$276.5M
Aeroflow Inc.	NC	Durable Medical Equipment & Medical Supplies	$0	$571.9M
Zoll Services LLC	PA	Durable Medical Equipment & Medical Supplies	$0	$503.8M

Nearby Providers

Other providers in the same ZIP code as Accredo Health Group Inc, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Memphis Pathology Laboratory	TN	Clinical Medical Laboratory	$14.8M	$61.4M
Support Solutions Of The Mid-south	TN	Community/Behavioral Health Agency	$0	$45M
Fred Thomason	TN	Psychiatry Physician	$0	$25.8M
Infusion Partners LLC	TN	Home Infusion Therapy Pharmacy	$0	$19.8M
Miller Dental Health	TN	Pediatric Dentistry	$0	$12.6M
Alliance Health Services Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$11.2M
Joseph Ruder	TN	General Practice Dentistry	$0	$7.1M
Helpful Hands, LLC	TN	In Home Supportive Care Agency	$0	$6.6M
Brink & White Pediatric Dental Associates, PLLC	TN	Pediatric Dentistry	$0	$4.7M
Shelby County Government	TN	Land Ambulance	$940.1K	$3.6M

Accredo Health Group Inc — Billing Profile & Reimbursement Data

Sign up for Accredo Health Group Inc — Billing Profile & Reimbursement Data policy alerts

Accredo Health Group Inc — Billing Profile & Reimbursement Data

Sign up for Accredo Health Group Inc — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicaid: Total Revenue Breakdown by CPT/HCPCS Code

Medicaid: Complete Services Breakdown

Medicaid: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References